Zeskind Benjamin J. 4

What Happened

• Benjamin J. Zeskind, President, CEO and a director of Immuneering Corp (IMRX), received a grant/award of 688,000 derivative securities on February 3, 2026. The reported acquisition shows $0.00 per share (no cash paid at grant). The award is reported on a Form 4 as transaction code "A" (grant/award).

Key Details

• Transaction date: 2026-02-03; filing date: 2026-02-05 (timely within Form 4 reporting window).
• Amount: 688,000 derivative shares reported at $0.00 per share (total reported consideration $0).
• Vesting: per footnote — vests in equal monthly installments over a four-year period beginning Feb 1, 2026, and fully vested on Jan 1, 2030.
• Type: reported as a derivative award (Form 4 shows derivative security); no immediate sale or cash exercise reported.
• Shares owned after the transaction: not specified in the details provided here.
• No indication this filing was late.

Context

• This is a compensation grant (award) rather than an open-market purchase or sale. Such awards are common for executive pay and vest over time to align incentives; the economic value to the insider depends on future share price and the award’s exact form (RSUs, options, or other derivative), which the filing lists as a derivative but does not detail beyond the vesting schedule.